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Abstract: Meningitis is commonly caused by infection with a variety of bacterial or viral pathogens.
Acute bacterial meningitis (ABM) can cause severe disease, which can progress rapidly to a critical
life-threatening condition. Rapid diagnosis of ABM is critical, as this is most commonly associated
with severe sequelae with associated high mortality and morbidity rates compared to viral meningitis,
which is less severe and self-limiting. We have designed a microarray for detection and diagnosis
of ABM. This has been validated using randomly amplified DNA targets (RADT), comparing
buffers with or without formamide, in glass slide format or on the Alere ArrayTubeTM (Alere
Technologies GmbH) microarray platform. Pathogen-specific signals were observed using purified
bacterial nucleic acids and to a lesser extent using patient cerebral spinal fluid (CSF) samples,
with some technical issues observed using RADT and glass slides. Repurposing the array onto
the Alere ArrayTubeTM platform and using a targeted amplification system increased specific
and reduced nonspecific hybridization signals using both pathogen nucleic and patient CSF DNA
targets, better revealing pathogen-specific signals although sensitivity was still reduced in the latter.
This diagnostic microarray is useful as a laboratory diagnostic tool for species and strain designation
for ABM, rather than for primary diagnosis.
Keywords: meningitis; microarray; bacterial; diagnostic; assay; ArrayTube; diagnosis; infection
1. Introduction
Meningitis is a disease caused by inflammation of the meninges, the cause of which is generally
associated with infection [1–3]. It can present acutely or chronically with less severe symptoms over
a prolonged period. Acute meningitis is a syndrome defined by meningeal symptoms (headache,
neck stiffness, vomiting, and photophobia) in conjunction with cerebral dysfunction (confusion, coma)
and progresses over hours to days. The cerebral spinal fluid (CSF) often presents with leukocytosis.
The most common causes of acute meningitis in the United Kingdom are bacterial and viral infection.
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Viral infections are responsible for aseptic meningitis syndrome, which is characterized by
a lymphocytic pleocytosis in the CSF and negative bacterial cultures. However, this form of
meningitis can be mimicked by intracellular bacterial infections including Rickettsia spp., Leptospira spp.
and Mycobacterium tuberculosis. Acute viral meningitis (AVM) tends to occur in epidemics and is
usually a mild, self-limiting disease in the immunocompetent patient. It can be caused by a wide range
of viral agents, but typically enteroviruses and herpesviruses [4–6]. Despite the usually mild nature
of these viral infections, they can also be associated with more serious acute viral encephalitis (AVE),
which has high mortality rates and survivors can develop chronic conditions, including significant
neurological deficits.
Acute bacterial meningitis (ABM) can cause more fulminant disease [3,7,8] and progression to
a critical life-threatening septicemia can be extremely rapid. This has high mortality and morbidity
rates if treatment is delayed or withheld [9–11]. The causes of ABM vary and are dependent on the
immune status and age of the patient and whether any recent head surgery or trauma has preceded
symptoms. The most common causes in healthy adults are Haemophilus influenzae, Streptococcus
pneumoniae (pneumococcal disease) and Neisseria meningitidis (meningococcal disease). In neonates,
the elderly and immunocompromised individuals Escherichia coli, Streptococcus agalactiae (GBS) Listeria
monocytogenes and Mycobacterium tuberculosis are the prevalent pathogenic causes. Staphylococcus aureus,
Staphylococcus epidermidis, and Cutibacterium acnes can be the causative agents in postcranial surgery
and CSF shunts and trauma and need to be excluded during primary diagnosis [12,13].
In the early stages of disease the etiological agents responsible for ABM, AVM, and AVE are
extremely difficult to diagnose due to clinical symptoms of a diffuse and nonspecific nature [14–16].
Therefore, empirical treatments of Ceftriaxone and Acyclovir, plus or minus Dexamethasone
or Amoxicillin are administered a soon as possible and pre-emptive isolation of the patient is
undertaken until a diagnosis is made [17]. Currently, a combination of predictive factors are
used to form an initial differential diagnosis, including clinical presentation, CSF cell count
and biochemistry investigations [18]. This is then followed by CSF viral PCR and bacterial
culture. Serology and imaging of the brain may help to confirm a diagnosis and inform treatment.
However, some causative agents e.g., N. meningitidis, can be difficult to recover using culture-based
methods, in part due to the usual practice of administering antibiotics prior to patient sample
collection [19,20]. Many diagnostic laboratories therefore augment their diagnostic capabilities
with the use of molecular methods for identification of meningitis-associated bacterial [21,22]
and viral pathogens [23–26], although implementation of these is not comprehensive. These are
primarily real-time qualitative Polymerase chain reaction assays (RT-PCR), which are available for a
limited number of meningitis-associated pathogens. In addition, there are some molecular tests
available to discriminate between different bacterial species or serogroups; e.g., N. meningitidis
serogroups B, C, Y and W135 [27–30], S. pneumoniae [11] and H. influenzae [31]. Serogrouping of
most meningitis-associated strains is conducted using a range of methods e.g., culture, serology and
immunological tests at reference laboratories [14] and more latterly sequencing [32], however there is
still a need for harmonization of methodologies between laboratories [33].
There is a need for development of other rapid and sensitive diagnostic methods with the
capability for simultaneously assaying for multiple bacterial and viral agents and which discriminate
between different strains and serogroups. To facilitate this development we have investigated the use
of microarrays as a solution for rapid molecular pathogen identification of ABM. These have been the
focus of considerable attention in previous years for a range of analytical processes [34–36]. The use of
these multiplexed analysis systems has been widely accepted previously, as a means for augmenting
frontline traditional diagnostics, as they offer many advantages over traditional monoplex molecular
technologies. Microarrays are also highly amenable to multiplexing, obviating the need for multiple
tests per patient [37,38], with the potential for saving time and cost. Microarrays have further benefits
over established block-based or real-time PCR tests because they require less prior knowledge of the
infectious agent [39–42].
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Diagnostic microarrays have previously been developed for detection of bacteria and viruses from
both environmental and clinical sources. A number of groups developed low-complexity diagnostic
microarrays for identification of microorganisms in water and food samples [43–45]. They have also
been developed for detection of pathogens in clinical material based on genus and/or species-specific
oligonucleotide probes designed from database gene sequence alignments, including viral [46–49],
bacterial [50–53], fungal [54] and eukaryotic pathogens [55,56]. Wang and De Risi and colleagues
developed a number of arrays for detection of known viral and emerging viral pathogens using
hybridization to species-specific oligonucleotide probes [57–59] and using advanced bioinformatics
analysis tools to reveal pathogen-specific signal patterns [60]. Similar methodologies have been used
by these and other groups to identify meningitis-associated and emerging pathogens, including the
severe acute respiratory syndrome (SARS) coronavirus [61–64]. Here we present development and
validation of a meningitis diagnostic microarray; it’s reconfiguration onto the Alere ArraytubeTM
(Alere Technologies GmbH, Jena, Germany) platform and provide recommendations for its use in a
diagnostic setting.
2. Materials and Methods
2.1. Culture of Bacterial Pathogen Strains and Nucleic Acid Purification
All bacterial species and strains used in this study are shown in Supplementary Material S1,
Table S1. N. meningitidis strains representing serogroups A, B, C and W135, N. flavescens and N. lactamica
strains 020 & Y92-1009 were sourced from Prof. A. Gorringe, Meningitis Research Group, PHE,
Porton Down, UK. All other N. meningitidis strains were obtained from the National Collection of Type
Cultures, Colindale, London UK. Genomic DNA from all Neisseria strains were purified as follows.
Bacteria were cultured overnight on 5% horse blood/brain heart infusion agar plates at 37 ◦C; colonies
were isolated and resuspended in 200 µL Tris EDTA Glucose (TEG) buffer (10 mM Tris-Cl pH 8.0, 1 mM
EDTA, 2% glucose), then 500 µL guanidine hydrochloride lysis buffer (8 M guanidine hydrochloride,
0.2% sodium sarkinosate) was added to the bacterial suspension which was then mixed by inversion.
Two-hundred microliters of chloroform were then added to the emulsion which was centrifuged
at 13,000× g for 10 min. The DNA was recovered from the upper aqueous layer by precipitation
with 100% ethanol and collected by centrifugation. After washing twice with 70% ethanol the DNA
pellet was air dried and re-suspended in TE buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA), then stored
at −20 ◦C prior to use. Purified nucleic acid samples from other nonmeningococcal bacteria were
obtained from coworkers at Public Health England, Southampton, UK (PHES).
2.2. Collection of Human Donor Blood and Patient Cerebrospinal Fluid Samples and Purification of
Nucleic Acids
Seven CSF samples were collected initially at Public Helath England (PHE) for routine testing
for meningitis pathogens. Retained clinical samples acquired for diagnostic purposes are a valuable
resource and PHE has dispensation to use anonymised patient material for performance assessment,
this lies outside the Human Tissue Act 2004 (according to RCPath guidelines G035 [65]. These were
processed for DNA nucleic acids as pellet and supernatant fractions using a modification of the QIAamp
DNA Mini Purification Kit (Qiagen, Skelton House, Manchester, UK), as follows. CSF samples were
centrifuged for 5 min at 1000× g to remove cellular debris, 200 µL aliquots of the supernatant fraction
were then removed and centrifuged further at 13,000× g for 10 min. The pellet and supernatant
fractions were recovered and processed separately. The pellet fraction was resuspended in 200 µL of
TE buffer prior to further processing. Nucleic acids from each pellet and supernatant fraction were
then purified using the Qiagen QIAamp DNA Mini Kit according to the manufacturer’s instructions
recovered nucleic acids were stored frozen at −20 ◦C until required. Human AB whole blood was
purchased from Sigma (Sigma-Aldrich, Dorset, UK) and whole blood DNA purified using the QIAamp
DNA blood mini kit (Qiagen), according to the manufacturer’s instructions.
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An additional 146 CSF samples were collected by lumbar puncture for suspected bacterial or viral
meningitis/encephalitis between March and November 2011 at PHES. The volumes of CSF obtained
differed between patient samples, therefore phosphate buffered saline (PBS; Sigma, Dorset, UK) was
added to low volume samples below the minimum extraction volume, to make a final total volume of
200 µL. Nucleic acids were then purified using the QiaSymphony automated DNA extraction platform
and the QiaSymphony DSP virus/pathogen mini-kit, according to the manufacturer’s instructions
(Qiagen). All pathogen, human blood and patient DNA samples were quantified by spectrophotometric
analysis at 260 nm prior to use.
2.3. Design of Oligonucleotide Microarray Probes
The oligonucleotide probes used in this array were a mixture of 50 and 70-mers (all sequences are
given in Supplementary Material S2, Tables S2 and S3). Genus-specific probes were designed from
alignments of 16S rRNA sequences as described previously [66]. All other oligonucleotide probes e.g.,
for the sialyl-transferase genes of N. meningitidis, were designed from alignments of bacterial species or
strain-specific gene sequences using the Clustal W function [67] of either Megalign [68] or Bioedit [69].
Seventy-mer regions of low sequence conservation were selected, which differed significantly from
other closely related species or strains and which were discriminatory for the requisite pathogen.
The species or strain specificity of these probes was confirmed using database search algorithms
e.g., BLAST [70]. Oligonucleotides probes with greater than 90% sequence identity with other
closely-related bacterial gene sequences were excluded. The relative melting temperatures (Tm) of each
probe was calculated and those with a Tm of 60 ± 8 ◦C were selected. The suitability of the selected
oligonucleotides for their use as discriminatory probes with respect to low self-complementarity and
hairpin loop formation was also assessed using the algorithm Oligonucleotide Calculator), prior to
inclusion on the array.
2.4. Printing of Microarray Oligonucleotide Probes in Glass Slide Format
All 50- and 70-mer bacterial species and strain oligonucleotide probes for the glass slide format
microarray were synthesised by Illumina (Illumina, Cambridge, UK) and printed in quadruplicate
onto epoxy-coated Nexterion E slides (Schott Ltd., Stafford, UK) using a BioRobotics Microgrid II
gridder (Digilab Inc., Hopkinton, MA, USA). Oligonucleotides were diluted to a final concentration of
20 µM in 1.5× saline-sodium citrate buffer ((SSC) 25% dimethyl sulfoxide and 0.005% (w/v) sodium
dodecyl sulphate) prior to printing. The slides were then air-dried, baked at 80 ◦C for 2 h and stored
with desiccant at ambient temperature in the dark prior to use.
2.5. Amplification and Cy3-Labelling of Purified Nucleic Acids and Hybridization to the Meningitis Glass
Slide Array
All hybridizations in this study were conducted using Cy3-labelled DNA targets from either
purified pathogen genomic, human blood or patient CSF DNAs. The method used to generate
randomly amplified DNA targets is a modification of a previously published method [71] and has
been described previously [72].
2.5.1. Hybridization to Pan-Pathogen Arrays Using Randomly-Amplified Cy3 Labelled Targets and
the Manual Hybridization Method
Glass slide format microarray slides were hybridized with amplified, Cy3-labelled target DNAs as
published previously [53], with minor modifications. Slides were prehybridized in 5× SSC, 0.1% SDS
and 4× Denhardts solution (Sigma-Aldrich), washed in sterile, nuclease-free water, followed by 100%
isopropyl alcohol then air-dried. Cy3-labelled randomly-amplified target DNAs were denatured at
95 ◦C for 3 min then diluted to a final concentration of 80 µg/mL in 5× SSC buffer (Sigma-Aldrich),
0.1% SDS, 4× Denhardts solution. Forty microlitres of this hybridization mix were then applied to the
microarray slide, covered with a glass coverslip, placed in a humidified multislide chamber (Genetix
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Inc., Wallsend, UK), then incubated at 50 ◦C for 16 h. The slides were then washed once in each of
the following buffers for two minutes: (A) 1× SSC, 0.2% SDS, 50 ◦C, (B) 0.1× SSC, 0.2% SDS, 50 ◦C,
(C) 0.1× SSC, 0.2% SDS, 20 ◦C, then centrifuged to dryness at 213× g for 5 min then scanned using an
Affymetrix 428 microarray laser scanner at a gain of sixty.
2.5.2. Hybridization to Pan-Pathogen Arrays Using Randomly-Amplified Cy3 Labelled Targets Using
the Advalytix Slidebooster™ Hybridization Station.
Nonspecific hybridization to unrelated oligonucleotides was observed to a number of
oligonucleotide probes on the array, using both pathogen and nonpathogen labelled nucleic acids.
To address this issue and to attempt to reduce these events, nonmanual hybridizations were conducted
using a Advalytix Slidebooster™ hybridization (Beckman Coulter UK, High Wycombe, UK) and
wash station with addition of a blocking agent i.e., Denhardts solution and 16% formamide to the
hybridization buffer to reduce background from nonspecific hybridization [73].
Microarray slides were prehybridized as described for manual hybridizations then placed array
side up into a Slidebooster hybridization chamber containing sonic agitation chips, with coupling
fluid placed between the slide-base and the platform, according to the manufacturer’s instructions.
Lifter-slips were then placed on the slide, gasket side down and the slide left to preheat to 50 ◦C,
prior to addition of labelled target. Preprepared target DNAs (Cy3-labelled randomly-amplified targets
DNAs denatured at 95 ◦C for 3 min, then diluted to a final concentration of 120 µg/mL in 5× SSC,
0.1% SDS, 4× Denhardts solution, 16% formamide at 50 ◦C) were then applied to the Lifter-slip
edge, drawing the labelled target onto the array by capillary motion. Use of this platform was found
also to significantly reduce the time of incubation needed. Thus, the slides were then incubated at
50 ◦C for six hours, at a maximum mixing power of 27. After incubation the slides were removed,
placed in an Advawash™ chamber and washed according to the protocol for manual hybridizations
described above. The slides were centrifuged to dryness at 213× g for 5 min and then scanned using
an Affymetrix 428 microarray laser scanner at a gain of sixty.
2.6. Data Processing and Analysis
For glass slide array hybridizations, files were saved in Tiff format after image capture,
then quantified using the scan analysis software Bluefuse™ (BlueGnome Inc., Cambridge, UK), all data
were normalized to the global median for each slide then replicate data points fused according to
median fluorescent intensity and identity. The data was log-transformed log2() function in “R”. [74].
To identify probes with significantly higher Fluorescence a Z-score analysis was undertaken [75].
The Z-score is the number of standard deviations a given spot intensity is away from the mean,
and therefore a measure of which signal(s) differ significantly from the expected value.
Zi =
Si − µ
δ
where Zi is the Z-score for the ith spot, Si is the fluorescent intensity of the ith spot, µ and δ are the mean
and standard deviation of all sample spot intensities, Z-scores are then converted into probabilities.
In this study probability values were calculated directly from the intensity data using the pnorm()
function of ‘R’ base package [74]
p <−1 − pnorm (Si, µ, δ) (1)
Probes were sorted lowest to highest p-value and those with less than a user-defined cut-off (in
this case ≤0.2) were considered positive. Pathogen species and serogroups assignations were given to
each test target based on the number of significant generic, species-specific and/or serogroup-positive
probes in any given ranked data set. Fluorescence intensities for all raw data points were depicted
pictorially in heatmap format using an algorithm written in the statistical package ‘R’, published
previously [74,76].
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2.7. Reconfiguration of the Pan-Pathogen Array in Alere ArrayTube™ Format
Microarray hybridizations in glass slide format are not readily amenable for use as a routine
diagnostic assay, as there are limitations in terms of assay set up, ease of use and scale-up for
high-throughput. We therefore decided to transition our best performing validated detection probes
to an alternative assay format which would be more amenable to routine diagnostic laboratory use.
A selection of our preferred best performing meningitis-associated bacterial probes were chosen for
transition onto the ArrayTubeTM system, using information on probe performance ascertained from
prior validation of the array in glass slide format. A more focused bacterial meningitis array probe
set was constructed for evaluation of this form set, which included probes for N. meningitidis strains
A, B, C, X, Y, W135 and L, H. influenzae, S. agalactiae, S. pneumoniae, S. aureus and L. monocytogenes
plus additional test and control probes (for pathogens Mycobacterium tuberculosis, Escherichia coli K12,
Human G6PD1, PGK1 and B2M1 and Arabidopsis thaliana control sequences (Supplementary Material
S2, Table S3). All DNA probe sequences were synthesised and printed in ArrayTubeTM format by
Alere Technologies GmbH, Jena, Germany.
2.8. Development of a Targeted DNA Amplification and Labelling System Using VisualOMP Primer
Design Software
Primers for a targeted amplification system were designed in VisualOMP (DNASoftware, ANN
Arbor, MI, USA), using a database of imported probe and gene target sequences. The software
provides a means for in silico modelling of multiplex amplification steps. This modelling process
provides a solution for rational design of comprehensive multiplex specific primer sets, with similar
physiochemical parameters using uploaded gene sequences as a reference. All gene sequences from
which the microarray probes had been designed (excluding bexA) and those for newly designed test
and control probes were uploaded into the program and modelled using default settings. Final select
primer pairs were again assessed for specificity by comparison with database sequences using the
BLAST algorithm, before use [77]. These are given in Supplementary Material S3, Table S4.
2.9. Amplification and Labelling of Target DNAs and ArrayTube Hybridizations
All HPLC purified nucleotide primers were synthesized by Eurofins MWG Operon (Ebersberg,
Germany). A targeted, noncompetitive amplification system, based on the previously published
protocol of Bolander and coworkers [72], was used for amplification and labelling of target nucleic
acids in this study. Amplification and biotin labelling of all pathogen, control and human DNAs were
performed using Phusion Taq polymerase from Finnzymes (New England Biolabs, Hitchin UK), using
the following amplification protocol; 10.0 µL Phusion Taq buffer (5×), 125 µM dNTPs (excluding
dUTP), 75 µM dUTP and 75 µM Biotin-16–dUTP (New England Biolabs, USA), 0.5 µL Phusion Taq,
Primer Mix (0.5 µM each Primer final concentration), DNA Template 5.0 µL in a final volume of
50 µL. PCR amplification protocol—one cycle of 98 ◦C for 120 s, followed by 35 cycles of 98 ◦C for
15 s, 63 ◦C for 30 s, 72 ◦C for 45 s, with a final step of 72 ◦C for 420 s. Labelled target hybridizations
were conducted in printed ArrayTubesTM using the Alere hybridization protocol, according to the
manufacturer’s instructions (Alere Technologies GmbH) and using Poly-HRP Streptavidin (Fisher
Scientific-UK Ltd., Loughborough UK), with one minor alteration, using a final hybridization volume
of 200 µL. ArrayTubeTM incubations were performed on a Thermomixer Comfort Microtube shaking
heater block (Eppendorf UK Limited, Stevenage UK) and were read immediately after incubation with
substrate using an ATR03 ArrayTubeTM analyser. Hybridization signal intensities, data export and
analyses were conducted using Iconoclust ArrayTubeTM software according to the manufacturer’s
instructions (Alere Technologies Gmb). Mean intensities from each probe spotted in duplicate were
used in the analysis, probes with mean values ≥0.4 were considered positive, based on value cut-offs
established by Batchelor and colleagues [78].
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2.10. Real-Time Qualitative PCR Assays
To confirm the results obtained for pathogen target ArrayTubeTM hybridizations,
pathogen-specific RT-PCR assays were used. Multiplex meningitis-associated pathogen real-time
PCR assays were constructed based on either previously published assays for many of the bacterial
pathogens represented on the array e.g., Group B Streptococcus [79], H. influenzae [21,80], S. aureus [81],
S. epidermidis [2], N. meningitidis [14,82] and S. pneumoniae [83], or in house designed PHE assays,
where existing previously published assays were not available. Real-time PCR assays to the
meningococcal capsular transport gene ctrA were used for N. meningitidis, as previously described [21].
These assays had previously all been run in singleplex, however for ease of use in assaying large
numbers of samples these were reconfigured to run as three duplex assays (Supplementary Material
S4, Table S5). An additional assay for L. monocytogenes was sourced [84] and run in single-plex.
Real-time PCR primers and probes were synthesised by Eurofins MWG Operon (Germany).
A Taqman Universal Mastermix kit (Applied Biosystems Inc., Foster City CA USA) was used per the
manufacturer’s instructions and all assays were run on ABI 7500 Thermocyclers (Applied Biosystems
Inc., Foster City CA USA) All assays were validated using purified, species-specific pathogen nucleic
acids, prior to use on clinical samples. For the real-time PCR reaction, primers were used at a
concentration of 300 nM, and the internal, labelled probe at 200 nM, with 12.5 µL of TaqMan Universal
PCR master mix (Applied Biosystems Inc., Foster City CA USA). Five microlitres of sample were
added to generate a total reaction volume of 25 µL. Real-time PCRs were performed in 96-well reaction
plates as follows: 2 min at 50 ◦C, 10 min at 95 ◦C, 50 cycles, of 95 ◦C for 15 s and 60 ◦C for 60 s, probe
fluorescence was detected in the 530 nm channel, the assay was completed at 50 cycles.
3. Results
3.1. Hybridization of Randomly Amplified DNA Targets to the Meningitis Pan-Pathogen Glass Slide
Printed Array
All meningitis-associated bacterial pathogen and control human donor blood DNA samples were
randomly amplified, labelled with Cy3-dCTP and hybridized to the pan-pathogen array. The results
using randomly-amplified bacterial DNA targets hybridized to the meningitis array in glass slide
format using the manual hybridization methods and formamide-free buffers are depicted in heatmap
format in Figure 1. Exported data values were normalized to the global median, divided by the
human DNA control value for each probe, then significance values calculated for each probe set,
using the t-test function in Excel (one-tailed distribution, paired). Probes were ranked (highest to
lowest intensity), according to these corrected data values and using the data sort function in Excel,
from which species-specific probe hybridization profiles were discerned. Ranked data values for
each pathogen or control DNA and their associated significance values are depicted graphically in
Supplementary Materials S5 and S6. Most amplified bacterial genomic targets showed good specific
binding to their relevant species-specific probes. However some rogue nonspecific binding of bacterial
DNAs to unrelated probes was also observed, particularly with HAI3, HAIB1, NsG1, NsMB3, MsML5,
SPneu12 and StAU5. Although great care was taken in design to optimize oligonucleotide probe with
regards to secondary structure, specificity and melting temperature etc., these events may still be due
to residual secondary structure [85].
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3.1.1. Hybridization Profiling of Nonmeningococcal Bacterial Pathogens
Hybridizations to the meningitis array using H. influenzae strains HPA and Hi2, L. monocytogenes
strain Lm1, S. agalactiae strain Sa1, S. pneumoniae strain NCTC 07465 and S. aureus strains EMRSA-16
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and ATCC 29213 generated pathogen-specific hybridization profiles as expected (Figure 1A and
Supplementary Material S5), with some cross-hybridization to unrelated probes, as seen with all
samples including the human control DNA. Although the pattern of cross- hybridization with most
rogue probes (outlined above) was consistent, there was some minor variation in cross-hybridization
to nonspecific probes between different pathogen DNA targets.
DNA targets amplified from H. influenzae strains HPA and Hi2 gave good hybridization intensities
for seven of eleven of their species-specific probes. All probes for nucA and cpdB exhibited good
species specificity, but not those for bexA suggesting these latter gene probes are not useful as diagnostic
targets for H. influenzae in this study. These strains may perhaps be capsule deficient [86]. The amplified
DNA target from L. monocytogenes strain Lm1 showed good binding to all its pathogen-specific probes.
The DNA target from S. pneumoniae NCTC07465 bound well to the Streptococcus 16S rRNA generic
probes and nine of twelve of its specific probes. The DNA target from S. agalactiae strain Sa1 bound
well to the Streptococcus 16S rRNA generic probes and seven of eight of the specific probes. DNA
targets from S. aureus MRSA strain EMRSA-16 and MSSA strain ATCC29213 exhibited good binding
to all but two of the sixteen S. aureus specific probes (however, as described above StAU5 exhibited
a high degree of nonspecific binding to all bacterial DNA targets). Both S. aureus strains exhibited
significant binding to the N. meningitidis serogroup-specific probe NsMCD5. Nonfunctional probes
from S. pneumoniae, S. agalactiae and S. aureus did not appear to be specific to one gene as observed
with H. influenzae. Thus, certain probes from these nonmeningococcal meningitis-associated pathogens
exhibited target-specific hybridization profiles and show potential as diagnostic markers for the
relevant organism. Other probes exhibited minimal binding or cross-hybridization with unrelated
DNA targets and are not useful for future diagnostic development.
3.1.2. Hybridization Profiling of Meningococcal Bacterial Pathogens of Known Serogroup
Good hybridization fluorescence intensities were observed to N. meningitidis-specific
oligonucleotide probes with most Neisseria spp. amplified targets (Figure 1B, Supplementary Material
S5). The 16S rRNA probes Neiss 1 and Neiss 2 and ubi gene probes NsMA5 and NsMB4 gave
hybridization signals with all Neisseria spp. These probes, therefore, act as generic Neisseria probes.
The type IV pilin gene probe NsMA4, hybridized with most Neisseria spp. targets. The pilin gene
probes NsMB3 and NsG1 and the lcbA gene probe MsML5 showed nonspecific binding to other
nonmeningococcal DNA targets. NsMspp showed binding with the majority of N. meningitidis strain
DNAs with the exception of serogroups A, X, Z and Z-prime and the nonmeningococcal Neisseria spp.
Hybridization specificity to serogroup-specific probes generally corresponded well with the
serogroup of the relevant strain. N. meningitidis serogroup A strain Z5005 DNA target bound to
Neisseria generic probes and to all of the serogroup A probes (some of which exhibit some lack of
specificity, as discussed previously e.g., NsMA4 and NsMA5). It also bound to some other serogroup
probes, NsMZ1 and NsMW2. Thus, six of nine probes specifically designed for serogroup A exhibited
group serospecificity, all designed to the sacB gene. The remaining probes exhibited some cross-reactive
binding to other Neisseria spp. but not other non-Neisserial species bacterial DNA targets. Strains
NCTC10792 and NCTC10793, designated Z and Z-prime respectively, showed binding to NsMZ1;
NCTC10792 also bound to NsMA1. The Z serogroup-specific probe NsMZ1 does show binding with
other N. meningitidis strain targets e.g., serogroup A strains, however these also show binding to
their respective serogroup A-specific probes and are therefore easily distinguishable from Z strains.
Z strains show binding to NsMZ1 only (with some weak additional binding to NsMA1 with strain
NCTC10792). N. meningitidis strain Z4673 bound to the generic probes and all serogroup B-specific
probes, as did strains NCTC11423 and NCTC11424 (previously annotated as strains 73-M6 and 74-M24)
and not to serogroup A specific probes. These latter strains have therefore been previously incorrectly
characterized. Only probes NsMB1 and NsMB2 and NsMB5-NsMB7 are in fact specific for serogroup B.
N. meningitidis serogroup C and D strains Z8948 and NCTC9714 respectively showed binding
to the Neisseria generic probes and four of the five serogroup C/D probes. One of these latter
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probes showed nonspecific binding with other meningitis-associated bacterial targets; NsMCD5
exhibited binding with both NCTC9714 but also both S. aureus strain DNA targets. Thus, probes
NsMCD1-NsMCD4 are diagnostic for N. meningitidis serogroup C or D strains. Serogroup W135,
X and Y strains Z6904, NCTC10790 and NCTC10791 respectively, showed binding to both the generic
and their appropriate serogroup-specific probes; in addition, NCTC10790 bound to probe NsMZ1.
The human DNA control showed a high degree of cross-reactive binding to serogroup W probes
NsMW1, NsMW3 and NsMW4. Therefore, may not appear useful as significant identifying probes
for W strains, if used for patient clinical samples directly, but may be useful for typing of cultured
meningococcal strains. The majority of N. meningitidis strains exhibited a characteristic binding profile
indicative of their serogroup, which may be useful for diagnostic identification.
3.1.3. Hybridization Profiling of Meningococcal Bacterial Pathogens of Unknown Serogroup
Nine of eleven N. meningitidis strains of known serogroup demonstrated distinct binding profiles
to generic and serogroup-specific probes. We then went on to assess a further nine N. meningitidis
strains of previously unidentified serogroup with a view to assessing the potential of these probes
for serogroup identification (Figure 1C, Supplementary Material S5). In addition to binding to
Neisseria generic probes, N. meningitidis strains NCTC13152, NCTC13198, NCTC13214, NCTC13218,
NCTC13223, NCTC13273 and NCTC 13275 showed patterns of binding indicative of B serogroup
strains. Although strains NCTC13152, NCTC13198, NCTC13214, NCTC13273 and NCTC13275 showed
some limited binding to other serogroup-specific probes, the dominant profile was serogroup B. Strain
NCTC13225 showed the binding profile of serogroup A and strain NCTC13248 showed the binding
profile of serogroup Y. All previously un-serogrouped strains tested could be ascribed to a serogroup
by microarray hybridization profiling, however the capsule synthetic characteristics of these strains is
not known. Patterns of binding were not identical to previously tested serogroup strains, suggesting
some strain-specific gene sequence variation.
3.1.4. Hybridization Profiling of Nonmeningococcal Neisseria spp.
To ascertain the binding profile of nonmeningococcal Neisseria strains, amplified DNA targets
from three N. lactamica and one N. flavescens isolates were amplified, labeled, and hybridized to the
pan-pathogen array (Figure 1D, Supplementary Material S5). Clear binding to generic probes Neiss 2,
Neiss 1, NsMA5 and NsMB4 was observed with the N. lactamica and N. flavescens isolates. N. lactamica
strains HPA1 and 2006 also bound to NsMB3, NsG1 and NsML5, which also show cross-reaction with
other non-Neisseria spp. targets. N. lactamica HPA1 and 2009 bound NsMA4, N. lactamica HPA1 alone
bound to NsMX1. Therefore, in addition to expected binding to the 16S rRNA Neisseria-generic probes
Neiss1 and Neiss2, these nonpathogenic isolates bound to other Neisseria generic probes; however,
none bound to NsMA1, NsMspp or NsMZ1 (designed to the ctrA gene). These Neisseria spp. do appear
to share some genetic characteristics in common with pathogenic Neisseria in that they appear to carry
type IV pilin-like and ubiA gene loci.
3.2. Purification of DNAs from Patient CSF, Labelling and Array Hybridizations
We established that pathogen and serogroup-specific hybridization profiles could be identified
using our pan-pathogen array probe set, using highly pure pathogen DNAs as template. We therefore
sought to test the method on culture negative CSF samples from patients with suspected meningitis,
to establish whether pathogen-specific profiles could be identified. Nucleic acids were purified
from patient CSFs as described above. The quantities of total nucleic acid recovered and sample
nomenclature designations from these select patient CSF samples, are given in Supplementary Material
S8, Table S14. As can be seen small amounts of nucleic acids were recovered from patient CSF samples
after slow centrifugation to remove large cellular debris. Typically, there was a greater amount of DNA
in the supernatant than the pellet fractions (ranging between 0–750 ng/uL total nucleic acids).
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3.2.1. Hybridization Profiling of Patient CSF Target DNAs and Putative Pathogen Identification to the
Meningitis Array in Glass Slide Format
Randomly amplified targets from all seven patient CSF samples, supernatant (suffix S) and
pellet fractions (suffix P) were amplified, labelled and hybridized to the array as described above.
As a control to ascertain the degree of binding of pathogen-specific probes with a nonbacterial
pathogen target, randomly amplified targets with no added DNA or human donor whole blood
DNA negative controls were also hybridized to the array. Data were normalized to the global median
and ranked then according to significance (p ≤ 0.2) for all targets. The data for these hybridizations
are depicted in heat-map format in Figure 2 and Supplementary Material S6. Certain samples
produced data of high fluorescence binding intensity and good confidence e.g., CSF1S, CSF2P, CSF3P,
CSF5P. Pathogen-specific signals could be ascribed to these samples with some degree of confidence.
Other samples produced data of low fluorescence binding intensity and reasonably good confidence
e.g., CSF3S, CSF6P, CSF7S, and CSF7P to which pathogen-specific signals could be tentatively ascribed.
The remaining samples produced data of low fluorescence binding intensity and low confidence
e.g., CSF1P, CSF2S, CSF4S, CSF4P, CSF5S and CSF6S and no pathogen-specific signals could be
assigned. Putative Neisseria-specific hybridization profiles were seen with patient CSF samples, CSF1S,
CSF2P, CSF3S, CSF3P and CSF5P. However, no definitive serogroup identification could be made in
these samples, due to incomplete or mixed serogroup profiles. These showed some of the strongest
Neisseria-specific profiles. Somewhat weaker microarray binding profiles were also observed in
samples CSF6P, CSF7S and CSF7P. No species could be ascribed to the streptococci-containing samples,
again due to incomplete strain profiles. It could be seen therefore that a high degree of background
nonspecific hybridization was obtained using amplified DNA targets from patient CSF samples.
3.2.2. Further Development of Methods for Pathogen Identification in Patient CSF Samples to the
Meningitis Array in Glass Slide Format
We have shown previously that identification of pathogen-specific identification signatures was
achieved using highly purified pathogen nucleic acids and were observed tentatively with some
patient CSF DNA samples. This latter result may be due in part to low abundance of the bacterial DNA
and high nonspecific background signals from contaminating host DNAs. As the signal-to-noise ratios
with our existing hybridization buffers and protocols were not satisfactory, we sought to improve this
technical issue through the use of 16% formamide-containing hybridization buffers and an automated
hybridization station, the Advalytix Slidebooster™, to improve sample mixing during hybridization.
Patient CSF samples were again hybridized to the meningitis glass slide array, (as described in
Section 2.6). Samples of no added DNA, human Donor DNA, N. lactamica HPA1, N. meningitidis strain
Z5005 (Serogroup A), N. meningitidis strain Z4673 (Serogroup B) and S. agalactiae amplified targets were
used as negative and positive controls. The results were confirmed for N. meningitidis using real-time
PCR assay for the ctrA gene. The data obtained are shown in Figure 3 and Supplementary Material S7.
The combined data for all these hybridizations and real-time PCR results are summarised in Table 1.
Overall formamide-containing buffers gave lower fluorescence binding intensity signals, across all
probes. Addition of 16% formamide reduced overall signal intensities by approximately seven-fold.
There was an observed overall improvement in the signal-to-noise ratio and the nonspecific
hybridization to previously identified rogue probes e.g., StAU5 was greatly reduced. N. lactamica,
N. meningitidis strains Z5005 and Z4673 and S. agalactiae hybridizations gave strong pathogen-specific
binding signals to specific oligonucleotide probes, as expected for those sample DNAs. Data of high
fluorescence intensity and good confidence were obtained with some samples e.g., CSF1S, CSF1P,
CSF2P, CSF4S and CSF7P. Pathogen-specific signals could be ascribed to these samples, with some
degree of confidence. Data of low fluorescence intensity and reasonably good confidence were obtained
with other samples e.g., CSF3S, CSF4P, CSF6S, CSF6P and CSF7S; pathogen-specific signals could be
tentatively ascribed to these samples. The remaining hybridizations produced data of low fluorescence
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intensity and low confidence e.g., CSF2S, CSF3P, CSF5S and CSF5P; pathogen-specific signals could
not be ascribed to these samples with any degree of confidence.High-Throughput 2018, 7, x FOR PEER REVIEW  13 of 29 
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Figure 3. Fluorescence intensity of probe hybridization with amplified targets using patient CSF nucleic
acids, depicted in heat-map format. From the glass slide-printed meningitis microarray, hybridizations
using the Advalytix hybridization platform and formamide-containing hybridization buffer.
Thus, putative Neisseria-specific hybridization profiles were seen with patient CSF samples, CSF1S,
CSF1P, CSF2P, CSF3S, CSF4S and CSF4P, CSF6S and CSF6P and CSF7S. These results corresponded
more precisely with the results of the real-time PCR for N. meningitidis ctrA, as five out of six real
time-PCR (RT-PCR) positive samples were now correctly identified, although some RT-PCR negative
samples now appear positive e.g., CSF3S, CSF6P and CSF7S. These discrepancies may be due to the
fact that we are working at the limits of detection and there are likely to be sampling errors between
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different aliquots of the same sample. Tentative serogroup identification could be made in two of
the Neisseria-containing samples, serogroup X in CSF4P and serogroup C/D in CSF6S and CSF6P,
as hybridization to serogroup-specific probes were observed in these samples. A streptococci profile
was observed again in CSF7P. No specific species could be assigned for this sample.
Table 1. Details of processed patient cerebrospinal fluid samples and positivity for Neisseria meningitidis
using real-time polymerase chain reaction (RT-PCR) and microarray hybridization.
Patient SampleDesignation
Sample
Fraction Culture
RT-PCR Ct Values
for Neisseria
meningitides (ctrA) *
Microarray
Signal for
Neisseria spp.
1 CSF1S CerebrospinalFluid supernatant - 36 +
1 CSF1P CerebrospinalFluid pellet - 37 +
2 CSF2S CerebrospinalFluid supernatant - 35 -
2 CSF2P CerebrospinalFluid pellet - 31 +
3 CSF3S CerebrospinalFluid supernatant - ND -
3 CSF3P CerebrospinalFluid pellet - ND -
4 CSF4S CerebrospinalFluid supernatant - ND +
4 CSF4P CerebrospinalFluid pellet - 38 -
5 CSF5S CerebrospinalFluid supernatant - ND -
5 CSF5P CerebrospinalFluid pellet - ND -
6 CSF6S CerebrospinalFluid supernatant - 36 -
6 CSF6P CerebrospinalFluid pellet - ND -
7 CSF7S CerebrospinalFluid supernatant - ND -
7 CSF7P CerebrospinalFluid pellet - ND -
* CtrA RT-PCR conducted at PHES. ND: not detected.
3.3. Determination of the Infectious Pathogen in Patient CSF Samples Using Multiplex RT-PCR
All clinical samples in the larger secondary panel were assayed using RT-PCR assays for common
meningitis-associated pathogens (described in Section 2.9). Results of all RT-PCR-positive samples and
the paired associated culture results are given in Table 2. Eighteen CSF samples out of one hundred
and forty-six tested (~13%), were found to be positive for bacterial pathogens by RT-PCR. The majority
of these were found to contain S. epidermidis (10/18, ~54%), S. epidermidis and S. aureus (1/18, ~5%).
The remaining samples were found to contain either N. meningitidis (4/18, ~21%), H. influenzae (3/18,
~15%) or S. pneumoniae (1/18, ~5%). Only 3/18 were positive by bacterial culture, samples 14, 90 and
145 which also exhibited low Ct values, indicating a high amount of pathogen nucleic acid and vis á
vis the pathogen present.
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Table 2. Details of RT-PCR bacterial pathogen positive patient cerebrospinal fluid samples.
Sample
Number M/F
Date of
Sample
Syndromic
Meningitis PCR
(CSF Unless Stated)
Bacterial
Culture
White
Blood Cells
109/L
CRP
mg/L
Other/Clinical/
Travel History
4 F 25 June 2011 Ent, HSV1/2, VZV-ve no growth 4 <1
11 M 4 July 2011 N. meningitidis-ve no growth 11.7 16
13 F 1 July 2011 Ent, HSV1/2, VZV-ve N/A N/A N/A
14 F 5 July 2011 Ent, HSV1/2, VZV-ve S.pneumoniae 9.5 185
clinical details:
“pyrexia-strep
meningitis”; β
haemolytic
Streptococcus not
isolated
21 F 22 July 2011 Ent, HSV1/2, VZV-ve N/A N/A N/A
24
29 F 21 July 2011 Borrelia burgdorferi-ve N/A N/A N/A
34 M 28 July 2011 Ent, HSV1/2, VZV-ve N/A N/A N/A
51 F 30 March 2011 Ent, HSV1/2, VZV,N. meningitidis-ve no growth 7.8 13
54 F 4 April 2011 Ent, HSV1/2, VZV,N. meningitidis-ve no growth 18.6 <1
headache,
photophobia, recent
trip to Gambia
61 * M 13 April 2011
AdV, RotaVirus, Ent,
HSV1/2,
N. meningitidis-ve
no growth 10 6
63 * M 13 April 2011
AdV, RotaVirus, Ent,
HSV1/2,
N. meningitidis-ve
no growth 64 6
70 F 20 April 2011 Ent, HSV1/2, VZV-ve no growth 6 10
72 U 14 April 2011 B. burgdorferi-ve N/A N/A N/A
76 M 27 April 2011 Ent, HSV1/2, VZV-ve no growth 13.3 2
90 F 12 May 2011 Ent, HSV1/2, VZV-ve
mixed
perineal
flora
14.3 55 Pyrexia ofunknown origin
95 M 16 May 2011 Ent, HSV1/2, VZV-ve no growth 6.8
127 M 23 June 2011 Ent, HSV1/2, VZV,N. meningitidis-ve no growth <1
145 F 14 July 2011
Parvo, CMV,
EBV-ve (CSF).
N. meningitidis-ve
(blood) Varicella IgG
detected (blood)
N. meningitidis
in blood
bottle
60
Ref lab report: Type
B, subtype
P1.7/P1.1/NT;
porA seq:
7-1/1/35-1
147 F 4 June 2011 Ent, HSV1/2, VZV,N. meningitidis-ve no growth <1 7
CRP: C-reactive protein, N/A: not available, * repeat sample from same patient.
3.4. Redevelopment of the Meningitis Array on the Alere ArrayTubeTM Platform
The meningitis array configured in glass slide format was useful for probe validation; however in
this format it has limited use in a routine diagnostic context. We therefore reprinted the best performing
probes on the Alere ArrayTubeTM system, using a specific target amplification system to improve the
specificity and sensitivity of hybridization. This was evaluated, using amplified, labelled bacterial
pathogen DNA targets and a larger cohort of patient CSF samples.
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3.4.1. Singleplex and Multiplex Target Amplification Using Purified Pathogen Nucleic Acids and
Hybridization to the Meningitis Array in ArrayTubeTM Format
Pathogen-specific primer pairs were assessed for amplification of their product in singleplex and
analyzed using gel electrophoresis (data not shown). These amplification products were then used in
singleplex hybridizations to the ArrayTubeTM reconfigured meningitis array (AMA), to confirm the
correct probe binding profile for each target. A viable multiplex amplification containing each target
primer pair was then constructed (tested at each stage with the requisite bacterial pathogen DNA and
using gel electrophoresis). Once a functional multiplex PCR was confirmed, this assay was again used
to generate biotin-labelled target amplicons, which were hybridized to AMA tubes, according to the
above-described protocol (select single and multiplex hybridization profiles using purified pathogen
nucleic acids are given in Figures 4 and 5 and Supplementary Material S9).High-Throughput 2018, 7, x FOR PEER REVIEW  17 of 29 
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DNA for N. meningitidis serogroups A-, B-, C- and W135- and patient CSF samples 4-, 13- and 14- and 
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Figure 4. Results of singleplex a plification and icroarray hybridization of select, biotin-labelled
amplified purified pathogen DNA targets and hybridization to the Alere ArrayTubeTM printed
meningitis microarray. (A) No template control singleplex amplification, (B) Streptococcus pneumoniae
singleplex amplification (Primers SPne1_2, 2.5 ng/mL target DNA), (C) Listeria monocytogenes singleplex
amplification (Primers LiMo4_6, 2.5 ng/mL target DNA), (D) Staphyl aureus singleplex amplification
(Primers StAUB_3, 2.5 ng/mL DNA). (E) N. meningitidis Serogroup B singleplex amplification (Primers
NsMB4, 2.5 ng/mL DNA), (F) No template control multiplex amplification, (G) S. pneumoniae multiplex
amplification, (H) L. monocytogenes multiplex amplification, (I) S. aureus multiplex amplification,
(J) N. meningitidis serogroup B multiplex amplification.
The hybridization patterns were as expected for each pathogen for both single and multiplex
hybridizations, revealing hybridization of the expected amplified product to the correct probe(s),
as expected. However, the multiplex hybridizations again revealed nonspecific binding to rogue
probes e.g., HAIB1, MTB3, 4, NsMA5, NsMapp, StAU5, SPne12. A number of these nonspecific
hybridization events were seen previously using the glass slide printed arrays. This appears to be a
technical issue as a function of multiplex amplification of targets and it is apparent that this is platform
independent. Hybridization to these rogue probes was also observed using negative control DNAs,
these signals could be filtered out or used to baseline other test hybridization profiles
During data analyses or the probes removed from the array. Addition of 16% formamide to the
glass slide configured array removed this background cross-hybridization; we therefore surmise that
these are due to secondary structure binding events of unknown origin.
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Figure 5. Multiplex RT-PCR (from [82]) for N. meningitidis and S. pneumoniae with purified pathogen
DNA for N. meningitidis serogroups A-, B-, C- and W135- and patient CSF samples 4-, 13- and 14- and
no template control. An ArrayTubeTM multiplex amplification hybridization image for CSF sample 14
is depicted alongside the RT-PCR trace.
3.4.2. Multiplex Target Amplification Using Purified Pathogen Nucleic Acids and Hybridization to the
Meningitis Array in ArrayTube™ Format Using Patient CSF Samples
Microarray hybridization targets were amplified from all bacterial RT-PCR-positive clinical CSFs
from Table 2. All clinical sample and negative control hybridizations are given in Supplementary
Materials S10 and S11 and are summarised in Table 3 with select hybridizations for samples C4,
C14 and C72 in Figure 6. Ten of twenty clinical CSF samples gave results concordant with that of
the RT-PCR assays. C4, C13, C72 and C145 were confirmed as N. meningitidis positive, three of the
strains were identified as serogroup A and one as serogroup B. C4, C29 and C34 were confirmed as
S. epidermidis and C29 additionally with streptococci pp. C14 was confirmed as S. pneumoniae positive,
C21 as H. influenzae positive and C24 as Group B streptococci positive. Interestingly C54 and C63
showed a hybridization pattern indicative of S. pneumoniae, in addition to the expected S. epidermidis
signal, which may indicate a mixed infection. The S. pneumoniae signal was not detected using RT-PCR,
but a clear signal could be seen using microarray hybridization. C127 displayed a hybridization
pattern for H. influenzae. Thus there appeared to be an incomplete correlation between the RT-PCR and
microarray hybridization results. The microarray may be detecting pathogen signals in the samples
not detected using RT-PCR and vice versa, which may be due to sampling errors.
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Table 3. RT-PCR Values of Bacterial Spp.-Positive Clinical Samples and Corresponding Array Result.
See Supplementary Material S11.
Sample
Number Bacterial RT-PCR Result Ct Value
Microarray Hybridization
Result Multiplex
Probable Strain
Designation
4 Neisseria meningitidis 43.72 N. meningitidis N. meningitidis A
11 Staphylococcus epidermidis 43.28 N. meningitidis/Staphylococcusspp. unknown
13 Neisseria meningitidis 39.88 N. meningitidis N. meningitidis A
14 Streptococcus pneumoniae 31.85 S. pneumoniae *
21 Haemophilus influenzae 37.34 ND
24 Group B Streptococci 36.39 ND
29 Staphylococcus epidermidis 36.48 ND
34 Staphylococcus epidermidis 38.8 S. pneumoniae *
51 Staphylococcus epidermidis 39.37 L. monocytogenes *
54 Staphylococcus epidermidis 38.79 S. pneumoniae
61 Staphylococcus epidermidis 37.59 N. meningitidis N. meningitidis A *
63 Staphylococcus epidermidis 40.66 S. pneumoniae/Staphylococcusspp. *
70 Haemophilus influenzae 40.36 ND
72 Neisseria meningitidis 36.00 N. meningitidis N. meningitidis A
76 Staphylococcus epidermidis &Staphylococcus aureus
37.87,
45.13 ND
90 Staphylococcus epidermidis 39.02 ND
95 Haemophilus influenzae 36.02 S. pneumonia *
127 Staphylococcus epidermidis 40.19 Neisseria spp.
145 Neisseria meningitidis 19.38 N. meningitidis/M. tuberculosis N. meningitidis B
147 Staphylococcus epidermidis 40.36 ND
ND: Not detected or indeterminate. * Denotes a weak signal.High-Throughput 2018, 7, x FOR PEER REVIEW  18 of 29 
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Sample 
Number 
Bacterial RT-PCR Result Ct 
Value 
Microarray Hybridization 
Result Multiplex 
Probable Strain
Designation 
4 Neisseria meningitidis 43.72 N. meningitidis 
N. meningitidis 
A 
11 Staphylococcus epidermidis  43.28 
N. meningitidis/Staphylococcus 
spp. 
unknown 
13 Neisseria meningitidis 39.88 N. meningitidis 
N. meningitidis 
A 
14 Streptococcus pneumoniae 31.85 S. pneumoniae * 
21 Haemophilus influenzae 37.34 ND 
24 Group B Streptococci 36.39 ND 
29 Staphylococcus epidermidis  36.48 ND 
34 Staphylococcus epidermidis  38.8 S. pneumoniae * 
51 Staphylococcus epidermidis  39.37 L. monocytogenes * 
6. ArrayTubeTM multiplex amplification hybridizat on mages for real-time-PCR positive patient
CSF sample (results summarized in Table 3). (A) Sample 4, (B) sample 14, (C) sample 72, (D) no
template control. See Supplem ntary Material S10.
4. Discussion
In this study, we describe development and use of a meningitis diagnostic microarray for specific
meningitis-associated pathogen detection, molecular serogrouping of previously identified strains
of N. meningitidis and for molecular serogrouping of previously unassigned strains. We previously
developed a pan-pathogen microarray based on conserved and species-specific bacterial and viral
sequences [66,71]. This was shown to be capable of specific pathogen identification using amplified
fluorescently labelled targets and to be useful in the discri i ation of closely-related Bacillus spp.
As part of further development to extend the capability of this pan- athogen array, we have now
designed a probe set for detection of five of the most significant ABM pathogens: N. meningitidis,
H. influenzae, S. agalactiae, S. pneumoniae, S. aureus and L. monocytogenes and other bacterial species.
We also included probes which would discriminate between the N. meningitidis serogroups A, B, C, W,
X, Y and Z [87].
Validation of the ABM probe set in glass slide format using the previously published random
amplification method [72] was initially conducted in order to validate the pathogen-specific probes,
using a method to limit bias toward known targets during amplification of test and control nucleic
acids. From the results presented here we conclude that the meningitis-associated oligonucleotide
probe set showed clear, specific hybridization patterns using randomly-amplified pathogen nucleic
acids, with manual hybridization methods and formamide-free buffers. Consistent pathogen-specific
profiles were observed with both nonmeningococcal and meningococcal pathogens with many of the
designed probes, with some evidence of strain differences where more than one strain was tested.
A small number of the specific probes did not function well as discussed or showed nonspecific binding
to a number of unrelated DNA targets. These nonspecific hybridization signals could be corrected
using a human DNA control; however they are not generally useful as diagnostic probes using this
hybridization protocol format. However, the limitations of this method are reduced sensitivity i.e.,
within a mixed pool of nucleic acids (i.e., pathogen and host in clinical CSF samples) the target of
interest may be in low concentration. Amplification and subsequent hybridization of nucleic acids
amplified equally in this mixed pool reduces the hybridization signal from specific targets of interest to
their oligonucleotide probes on the array. This reduces the overall sensitivity of detection. To ascertain
whether this could be due in part due to poor mixing during hybridization, we trialled the use of the
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Advalytix Slidebooster hybridization station, with and without the addition of formamide containing
buffers, to investigate whether we could ameliorate these technical issues.
Pathogen-specific profiles were obtained for H. influenzae, S. agalactiae, S. pneumoniae, S. aureus,
L. monocytogenes and all N. meningitidis strains tested. These probe sets were therefore valuable in
detection of the relevant organism. Some Neisseria group probes showed binding with many bacterial
DNA targets e.g., NsG1, NsMB3 and NsML5 and hybridized to nonpathogenic Neisseria spp targets
e.g., pilin-related protein probes NsMA4 and NsMB4, suggesting these have homologues in all of
the Neisseria strains examined. However, most serogroup-specific probes were highly discriminatory
and were found to correctly identify all previously serogrouped strains and to ascribe serogroups
to previously ungrouped strains. This profile information would be useful in determining the
serogroup of meningococcal strains which have no previous serogroup assignation. Other groups have
conducted similar studies; Swiderek et al. used a DNA microarray for multilocus sequence typing of
N. meningitidis [88], Coreless et al. characterized various N. meningitidis isolates using resequencing
DNA microarrays [61] and Lin used resequencing arrays to identify a range of different respiratory
tract pathogens [89]. Previous work has also demonstrated the utility of microarrays to serogroup
other bacterial pathogens e.g., E. coli, Shigella spp. [52,90,91] and streptococci spp. [92,93], to genotype
various pathogens associated with infection [48,94,95] and to detect antibiotic resistance genes in
Salmonella spp. [96] and S. aureus [97]. Therefore, these and other microarrays have proven utility
for both detection and simultaneous strain profiling of meningitis-associated species and strains and
additional functionalities.
Nonpathogenic Neisseria spp. including the commensal N. lactamica, showed binding profiles
to the Neisseria generic 16S rRNA probes; these and other probes in this study i.e., NsMA5 and
NsMB4 were identified as Neisseria generic probes. These nonpathogenic Neisseria spp therefore share
gene similarities with pathogenic N. meningitidis strains. Other groups have shown a general high
degree of gene conservation among Neisseria isolates, even in genes considered to be associated with
pathogenicity [84,88–90,98–101]. Type IV pilin-related proteins have been shown to be present in
many Neisseria spp including N. meningitidis serogroup B [91–93], N. gonorrhoeae [102] and in the
nonpathogenic strain N. lactamica [15,16]. Thus a proportion of the Neisseria probes were identified
as having utility for identification of all Neisseria spp, with an additional sub-set for more specific
identification of pathogenic N. meningitidis strains.
The meningitis-associated probe set was shown to correctly identify pathogen-specific profiles
using highly purified pathogen nucleic acid targets. With a view to future implementation of
this technology as a routine diagnostic tool, we wished to establish whether this method could
be used to identify pathogen signals in CSF samples from patients with suspected meningitis.
Randomly-amplified, labelled targets from purified CSF nucleic acids were hybridized to the
array using formamide-free manual hybridization methods. Recognisable pathogen signals were
detected in eight out of fourteen of the CSF samples tested. Amplified, labelled human nucleic acid
cross-hybridized to a significant degree with certain pathogen probes e.g., StAU5 and some of the
N. meningitidis W and X serogroup-specific probes. Although the background hybridization signals
with these samples were high and the signal-to-noise ratio poor, the hybridization patterns were
consistent over a number of experiments. Patient CSF targets have been re-amplified and hybridized
on a number of occasions with similar results being consistently obtained. These results are most likely
due to the presence of background host nucleic acid and a relatively low relative concentration of
pathogen nucleic acid in these samples, as evidenced by the high Ct values obtained using the real-time
PCR assays. These suggest that the concentration of pathogen DNA in these samples is limiting and
these diagnostic tests are likely to be operating at the very limits of detection. Improvements in signal
resolution were obtained through the use of improved data analysis methods and/or background
correction using a human DNA control, as discussed previously. However the presence of human
nucleic acids in these samples most probably still occludes the diminishingly small pathogen signal
due to its overwhelming abundance in the amplified target. Similar observations have been made
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using human patient sample materials with other bacterial or viral pan-pathogen arrays [103] As a
consequence other groups have developed complex bioinformatics approaches for resolving pathogen
microarray signals in a complex mix of host and pathogen nucleic acids [15,44,45,104]. The relatively
simple method for data correction to a hybridization control as described was useful for resolving
pathogen-specific signals in these CSF clinical samples; however further work would be required to
improve the efficacy of this hybridization format method for use in a clinical context.
In addition to improved data analysis methods, we sought to improve hybridization protocols
to reduce nonspecific background and improve signal resolution from cross-hybridization events.
A number of hybridization refinements were evaluated experimentally in an attempt to improve
the signal-to-noise ratio. These included prehybridization and hybridization blocks using tRNA,
salmon-sperm, mouse or human DNA and two-colour hybridizations using either human or mouse
amplified DNA targets in the second (Cy5) channel. None of these treatments had the desired effect of
improving the pathogen-specific signal. In addition, the presence of added foreign DNA was found
to block hybridization to probes designed to highly conserved genes from which good fluorescence
intensities had previously been obtained e.g., 16S rRNA probes. As an alternative we evaluated the
addition of formamide to our existing hybridization buffers and hybridization using an automated
hybridization station, the Advalytix SlideboosterTM. Various different protocols were tried including
varying formamide concentration and incubation time (data not shown), however we found that 16%
formamide (v/v) and six hours of incubation at maximum mix speed MP27 gave optimal results for
both pathogen and clinical DNA target hybridizations.
DNA targets from patient CSF samples CSF1S-CSF7P, controls without DNA, human donor DNA
controls, N. lactamica, N. meningitidis strains Z5005 and Z4673 and S. agalactiae were hybridized to the
array using the revised protocol. Addition of 16% formamide to the hybridization buffer was found
to significantly improve the resolution of the specific signal with all hybridized targets. Automated
hybridization methods in our experience appear to reduce nonspecific binding and improve the
signal-to-noise ratio. Pathogen-specific signals could be seen in a number of the clinical samples which
were detected more readily above background when compared with results obtained using manual
hybridizations, despite overall lower signal intensities. Pathogen signals were detected in ten out of
fourteen pellet or supernatant CSF samples tested, with clear recognisable signals for Neisseria species
in four of ten and Streptococci in one of ten samples tested. Although Neisseria spp. profiles were seen,
these could not all be ascribed precisely to a strain or serogroup; some indication of serogroup-specific
profiles was seen with samples CSF4P (serogroup X), CSF6S and CSF6P (serogroup C/D). However,
in the main, the fluorescence intensity of target binding to the serogroup-specific probes with all
N. meningitidis and CSF amplified targets was lower than to the generic probes e.g., Neiss1 and Neiss2.
This may reflect the nature of the genes from which these probes were designed, some genes being
present in multicopy e.g., rRNA genes, while others are present only in single copy. Hybridization
signals to single copy numbers genes including those for serotyping N. meningitidis strains were weaker
than those for multicopy genes.
Some strains of N. meningitidis do not contain the genes for capsule biosynthesis and would
therefore not be readily typed using either gene or protein capsule markers [105]. In addition,
other strains may exhibit phase variation of capsule and other outer membrane protein genes [106,107],
causing difficulties in classical serotype diagnosis of outbreak strains. These strains would still
be detectable and typeable using this microarray. In short, we improved hybridization specificity
using formamide-based buffers and the Advalytix Slidebooster hybridization station; however,
other technical issues still remain. In reflection this microarray method may not be suitable for
use as a front-line diagnostic assay, without further protocol refinements.
The array was also refocused and transferred to the ArrayTube™ platform (Alere Technologies
GmbH, Jena, Germany) to evaluate its use for development of high throughput front-line diagnostics.
This system is fully developed and more amenable to routine and high-throughput use than glass slide
format. These lower density microarrays offer a viable alternative because they can screen multiple
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targets simultaneously in a simple high-throughput system [108–111], are rapid, use inexpensive
reagents and would fit seamlessly into clinical laboratories [78,109]. This system was trialled and
confirmatory qPCR assays run in parallel for the same ABM targets using published and laboratory
developed assays. Transfer of the more focused array to ArrayTubeTM format was successful and a
proof of concept evaluation using purified pathogen nucleic acids and known positive patient CSF
samples showed promise, with clear serotyping profiles obtained for suspected N. meningitidis strains.
The targeted amplification system appeared to reduce nonspecific background hybridization signals
from human contaminating nucleic acids, thus overcoming some of the problems encountered using
the random amplification method. Some similar technical issues arising in the previous hybridization
protocol formats were observed here also, in particular nonspecific hybridization to certain probes.
These occurred consistently in sample and paired negative controls. For future use removal of these
rogue probes would be relatively straightforward, either during data processing or physically from the
array. The parameters for true positives explored by Batchelor et al. [78] and in [112] were useful as a
reliable method for setting cut-off values and enabled data processing and identification of significant
pathogen probe profiles. The colorimetric detection protocol is also faster and more efficient [113] and
would allow for higher-throughput sample processing and detection [109], a critical feature for use
within a clinical setting. Although some sensitivity issues remained at low pathogen concentrations
(as evidenced by high real-time-PCR Ct values) and modification of the protocol to include a targeted
amplification system, the ABM microarray format shows some promise as a diagnostic tool within a
clinical setting. Use of this pan-bacterial meningitis array could facilitate simultaneous detection of
diverse targets, negating the use of multiple separate assays, leading to improvements in time to result
in comparison to other molecular diagnostic tests. However, there are some limitations and the outputs
do not correspond precisely with those obtained by RT-PCR. This format does show some promise
for parallel and rapid detection of meningitis-causing pathogens, however further development work
would be required.
In summary, we aimed to develop a diagnostic test hybridization system based on generic
amplification of targets which would not require any prior knowledge of the organism and which
would not slant bias toward known pathogens. This was with a view to establishing a method that
could be used with either multiplex pathogen-specific pre-designed array sets or generic arrays such
as the noncognate arrays developed by Schrenzel and colleagues [42]. Many groups have designed
microarrays for detection of pathogens in clinical and environmental samples. However in the main,
these have utilized methods that amplify and hybridize specific PCR products complementary to the
pathogen-specific probes represented on the array. The FluChip microarray for detection of influenza
virus is one example of this microarray type and has already been validated for use in routine disease
diagnosis [114]. Other similar technologies include resequencing arrays which have been shown to be
useful for identification of pathogens [83,115], recombination microarrays to detect novel viruses [116]
and those that may be adapted for automated high-throughput pathogen detection [117]. Although we
chose deliberately to use the random-amplification method to reduce bias in generating targets from
material which may contain unknown pathogens, the limitation of the method is that it amplifies
all nucleic acids in the sample as well as those of any pathogen present. Overall, the array using
randomly-amplified targets showed good utility in detecting pathogen-specific signals using purified
pathogen nucleic acids, but was less efficient using clinical CSF sample material due to the technical
limitations outlined above.
Transfer to the ArrayTubeTM platform format and the use of specific amplification methods
showed the best potential with respect to generation of pathogen specific signals with the requisite
specificity and sensitivity of hybridization, as required for a routine diagnostic tool. The ability of
the assay to be rapid, efficient, specific and sensitive is essential for establishment of a robust assay
for routine use and this array may not be useful in that context without considerable further protocol
refinement. However, this would require more extensive optimization and at this present time its use
is most likely limited to species and strain typing from culture, within a laboratory setting. It could be
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useful in improving detection of diverse targets in meningitis in a laboratory setting using purified
pathogen nucleic acids, similar to other Alere ArrayTubeTM systems for detection and typing of
pathogens [118]. This test may facilitate more rapid species and strain designation, thus improving
time to diagnosis and improving clinical outcome. Similar types of assays have been developed
using Loop-Mediated isothermal Amplification methods [119], however these are run as independent,
single-tube reactions at present and currently lack multiplexing capacity.
5. Conclusions
Validation of the meningitis microarray in glass slide format, using randomly amplified DNA
targets, with and without the use of formamide-containing buffers was successful. However,
there were some technical issues with nonfunctioning and cross-hybridizing probes to bacterial
and human DNA control targets. This and the long and complex hybridization protocol not readily
amenable to high-throughput, limits the use and ongoing development of the array in this format.
Repurposing the array onto the Alere ArrayTubeTM format and using a targeted amplification system
was fruitful and clear pathogen-specific signals could be seen with pathogen DNA and clinical CSF
sample hybridizations. This would lend itself useful as a routine diagnostic tool in a laboratory
setting using purified pathogen nucleic acids, with the additional capability for N. meningitidis
serogroup identification.
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